EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Cost‐effectiveness analysis of osimertinib plus chemotherapy for patients with EGFR ‐mutated advanced non‐small cell lung cancer

Wentao Tian iD, Lishui Niu, Rongrong Zhou iD, Ziqi Wang, Jiaoyang Ning, Ruoyu Lu, Yin Shi, Zhaohua Tan

Cancer Medicine · 2024-08 · 13 (16)

DOI: 10.1002/cam4.70083 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, online erschienen am 29.08.2024. Verfasst von Wentao Tian und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Aniline Compounds, Acrylamides, Cost-Benefit Analysis. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Hunan Province, Chen Xiao-Ping Foundation for the Development of Science and Technology of Hubei Province, National Multidisciplinary Cooperative Diagnosis and Treatment Capacity Building Project for Major Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

First‐line osimertinib plus chemotherapy significantly prolonged progression‐free survival of patients with EGFR‐mutated advanced non‐small cell lung cancer (NSCLC) compared to osimertinib, according to the FLAURA2 trial.

Methods

We established a Markov model to compare the cost‐effectiveness of osimertinib plus chemotherapy with that of osimertinib alone. Clinical data were obtained from the FLAURA and FLAURA2 trials, and additional data were extracted from online resources and publications. Sensitivity analyses were conducted to evaluate the robustness of the findings. We used A willingness‐to‐pay threshold of $150,000 per quality‐adjusted life‐years (QALYs) gained. The main outcomes were QALYs, overall costs, incremental cost‐effectiveness ratio (ICER), incremental net monetary benefit, and incremental net health benefit. Subgroup analyses were conducted according to patients' mutation type and central nervous system (CNS) metastatic status.

Results

In a 20‐year time horizon, the ICER of osimertinib plus chemotherapy versus osimertinib alone was $223,727.1 per QALY gained. The sensitivity analyses identified the cost of osimertinib and the hazard ratio for overall survival as the top 2 influential factors and a 1.9% probability of osimertinib plus chemotherapy to be cost‐effective. The subgroup analyses revealed ICERs of $132,614.1, $224,449.8, $201,464.1, and $130,159.7 per QALY gained for L858R mutations, exon 19 deletions, CNS metastases, and no CNS metastases subgroups, respectively.

Conclusions

From the perspective of the United States health care system, osimertinib plus chemotherapy is not cost‐effective compared to osimertinib alone for treatment‐naïve patients with EGFR‐mutated advanced NSCLC, but more favorable cost‐effectiveness occurs in patients with L858R mutations and patients without baseline CNS metastases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungAniline CompoundsAcrylamidesCost-Benefit AnalysisLung NeoplasmsErbB ReceptorsAntineoplastic Combined Chemotherapy ProtocolsMutationQuality-Adjusted Life YearsHumansMarkov ChainsFemaleMaleProgression-Free SurvivalCost-Effectiveness AnalysisIndolesPyrimidines

Stichwörter der Autor:innen

EGFRchemotherapycost‐effectivenessnon‐small cell lung cancerosimertinib

Substanzen

osimertinibAniline CompoundsAcrylamidesErbB ReceptorsEGFR protein, humanIndolesPyrimidines

Autor:innen und Institutionen

  • Department of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
  • Xiangya Lung Cancer Center, Xiangya Hospital, Central South University, Changsha, China.
  • National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China.
  • Department of Pharmacy, Xiangya Hospital, Central South University, Changsha, Hunan, China.

ORCID-Profile: Wentao Tian, Rongrong Zhou

Förderung

  • Natural Science Foundation of Hunan Province
  • Chen Xiao-Ping Foundation for the Development of Science and Technology of Hubei Province
  • National Multidisciplinary Cooperative Diagnosis and Treatment Capacity Building Project for Major Diseases

Zitieren

APA

Tian, W., Niu, L., Zhou, R., Wang, Z., Ning, J., Lu, R., Shi, Y., & Tan, Z. (2024). Cost‐effectiveness analysis of osimertinib plus chemotherapy for patients with EGFR ‐mutated advanced non‐small cell lung cancer. Cancer Medicine, 13(16). https://doi.org/10.1002/cam4.70083

Vancouver

Tian W, Niu L, Zhou R, Wang Z, Ning J, Lu R, et al. Cost‐effectiveness analysis of osimertinib plus chemotherapy for patients with EGFR ‐mutated advanced non‐small cell lung cancer. Cancer Medicine. 2024;13(16). doi:10.1002/cam4.70083

BibTeX
@article{Tian2024,
  author = {Tian, Wentao and Niu, Lishui and Zhou, Rongrong and Wang, Ziqi and Ning, Jiaoyang and Lu, Ruoyu and Shi, Yin and Tan, Zhaohua},
  title = {Cost‐effectiveness analysis of osimertinib plus chemotherapy for patients with EGFR ‐mutated advanced non‐small cell lung cancer},
  journal = {Cancer Medicine},
  year = {2024},
  volume = {13},
  number = {16},
  doi = {10.1002/cam4.70083}
}
Kostenlos starten →